SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Londo who wrote (2585)1/18/2001 6:12:07 PM
From: aknahow  Read Replies (1) of 52153
 
Doubt XOMA represents a case of a short squeeze. Only a small percentage of the stock is short.

Sometime with the next 45 days, they will start a new clinical trial. Could be phase III but might be phase II. all expenses of the trial will be paid by BAX and possibly the start of the trial will result in further disclosure of the terms of the 10 year partnership agreement. Potential milestones will be above the $25 or $35 million allocated for the first indication, which was a small indication. Since the milestones were not all met only $10 million was actually earned.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News